Zenas BioPharma (USA)
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Zenas BioPharma (USA) sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Zenas BioPharma (USA): 5 sponsored US clinical trials, 3 recruiting.
Zenas BioPharma (USA) sponsors 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 3 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is IgG4 Related Disease, with 1 trials.
Upper-quartile sponsor footprint
Zenas BioPharma (USA) sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 3 |
What is open in the Zenas BioPharma (USA) pipeline
3 recruiting of 5 indexed (60% open).
Phase mix: 3 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: IgG4 Related Disease (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Zenas BioPharma (USA): open-pipeline peers nationwide
Peers matched on 5 registered trials and 60% open enrollment, not the therapeutic-area sidebar.
Zenas BioPharma (USA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 60% open enrollment (± trial volume)
- Alaska Native Tribal Health Consortium · 60% recruiting · 5 trials
- Anwaar Saeed · 60% recruiting · 5 trials
- Autolus Limited · 60% recruiting · 5 trials
- Beam Therapeutics · 60% recruiting · 5 trials
Related
What to do with this Zenas BioPharma (USA) page
5 registered trials is a research-attention snapshot, not an endorsement of Zenas BioPharma (USA) or any single study.
- 3 of Zenas BioPharma (USA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- IgG4 Related Disease is the condition Zenas BioPharma (USA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See IgG4 Related Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Zenas BioPharma (USA) pipeline card: 5 registered trials from official public datasets.Report a data error.